Engflag

Servex

Quick links to important sections

Servex

Servex_DE

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Servex

What is Servex? (Paclitaxel)

Here is a quick overview of Servex's core identity and composition, providing a clear foundation for what this medication is.

Property Description
Active ingredient Paclitaxel
Form Solution for intravenous (IV) infusion
Pharmacological Class Taxoid / Antimicrotubule agent
General Purpose Chemotherapy (Antineoplastic agent)
Origin Semisynthetic (derived from Pacific yew tree)

What Type of Medicine is Servex?

Servex is a trade name for the powerful chemotherapy drug Paclitaxel, which is classified as an antineoplastic agent—a medication designed to inhibit the growth of malignant tumors. It belongs to the taxoid class, a subgroup of antimicrotubule agents. Paclitaxel is clinically recognized as one of the most widely used and essential cytotoxic agents in oncology.

As an International Nonproprietary Name (INN), Paclitaxel forms the basis for numerous commercial preparations worldwide, including the original brand Taxol, which may differ primarily in their delivery systems and manufacturing.

Origin, Form, and Composition

Servex is typically administered as a clear solution for intravenous (IV) infusion directly into a vein. This method is required because the active compound, Paclitaxel, is not easily absorbed when taken by mouth and must be delivered systemically into the bloodstream.

The active ingredient is semisynthetic, meaning it was initially isolated from the bark of the Pacific yew tree (Taxus brevifolia) but is now routinely manufactured in a controlled setting. The conventional Servex formulation includes Paclitaxel combined with specific solvents (such as polyoxyethylated castor oil and alcohol) to allow the otherwise water-insoluble compound to be safely prepared for IV delivery.

How Servex Works to Stop Cancer Cells

Servex works by interrupting the ability of cancer cells to divide and create new copies of themselves. It achieves this by binding to and stabilizing the cell's internal structural supports (microtubules), which are essential for cell division.

By locking these structures in place, Servex prevents the cancer cell from completing its multiplication cycle, causing the cell to initiate programmed self-destruction, a process known as apoptosis. This mechanism is how the medication achieves its general purpose of eliminating rapidly proliferating cells and halting tumor growth.

Regulatory References

  1. Paclitaxel - NCI Drug Dictionary
  2. Paclitaxel Drug Information

What side effects are possible with Servex?

Possible Side Effects and Safety Information

The safety profile of Servex (paclitaxel) is structured around high-level adverse reaction classifications established by regulatory authorities. The primary safety concerns highlighted in official documents include Severe Myelosuppression and the potential for Severe Hypersensitivity Reactions.

Frequency and System Classification

Adverse reactions are formally categorized by their incidence according to regulatory standards:

  • Very Common (ge 1/10): These are the most frequent effects documented, primarily affecting the Blood and Lymphatic System (Neutropenia, Anemia), the Nervous System (Peripheral Neuropathy), and the Skin (Alopecia). Other very common reactions include Myalgia, Arthralgia, and Gastrointestinal effects such as Nausea and Mucositis.
  • Common (1/100 to <1/10): Reactions such as Thrombocytopenia, minor Hypersensitivity, and disturbances in the Vascular System (Hypotension, Bradycardia) are frequently reported.
  • Rare (1/10,000 to <1/1,000): These include rare, but clinically significant events like fatal Hypersensitivity reactions and certain severe Gastrointestinal disorders.

Serious Adverse Reactions and Safety Restrictions

Serious Adverse Reactions explicitly warned in regulatory documents are life-threatening infections resulting from Severe Neutropenia and acute, potentially fatal Anaphylaxis. Official labels document specific safety constraints:

  • Time-Related Pattern: Peripheral Neuropathy is defined as a cumulative and dose-related effect, while Hypersensitivity reactions are known to occur primarily during the first hour of infusion in early treatment courses.
  • Contraindications: The medicine is formally contraindicated in patients with a history of severe hypersensitivity to paclitaxel or the excipient Polyoxyl 35 Castor Oil, and specific baseline neutrophil counts must be met prior to initiation, reflecting regulatory safety limits. Patients with hepatic impairment also require careful consideration due to potential for increased toxicity.

Overdose and Emergency Response

Overdosage with Servex (Paclitaxel) is anticipated by regulatory authorities to cause an immediate escalation of known toxicities. The primary manifestations of high exposure are severe bone marrow suppression (myelosuppression), pronounced peripheral neurotoxicity, and mucositis (inflammation of the mucous membranes). Myelosuppression, which is the dose-limiting toxicity, can lead to life-threatening infection.

Urgent Medical Attention Required

Patients must seek immediate medical attention for any signs of a severe reaction or suspected overdose. The most critical, life-threatening outcomes documented in official labeling include severe hypersensitivity reactions (anaphylaxis), which may be fatal and present with difficulty breathing (dyspnea) or a significant drop in blood pressure (hypotension).

Management and Monitoring

There is no specific antidote known for Servex overdosage. Management therefore relies exclusively on symptomatic and supportive treatment to address the major toxicities. In overdose scenarios, regulators require continuous observation, including frequent peripheral blood cell counts to monitor bone marrow function and frequent vital signs monitoring to detect cardiovascular instability or acute hypersensitivity events. A specific consideration for pediatric patients involves the risk of acute ethanol toxicity from the drug's formulation solvent.

Therapeutic Uses of Servex

Managing Progression of Major Solid Tumors

Servex (Paclitaxel) is commonly used as a systemic management strategy for specific solid cancers, including ovarian carcinoma, breast cancer (particularly when involving the lymph nodes or spread to other organs), and certain forms of non-small cell lung cancer (NSCLC). The medication is also utilized for AIDS-related Kaposi sarcoma. This medication is applied in conditions marked by increased physiological stress and helps address symptom clusters that may become intense or disruptive, using the supportive relief that assists with maintaining functional stability. The key therapeutic benefit is supporting tumor burden management and disease stabilization, which may assist with maintaining functional stability and supporting general well-being during symptomatic phases.

Reducing the Risk of Cancer Recurrence

In certain clinical scenarios, Servex is applied as an adjuvant therapy following surgery to address microscopic, residual malignant cells. This strategy plays a role in managing the risk of the original cancer recurring. The practical benefit for the patient is contributing to a reduction in recurrence risk, which may support the patient's long-term health outlook after initial treatment. It is also relevant for managing advanced or metastatic disease, and applied in situations involving malignancies that may be resistant to initial therapeutic approaches.

“Servex is commonly used across conditions characterized by periods of heightened symptoms associated with systemic malignant disease and is relevant when supportive symptom management is appropriate.”

Quick Fact: Relief for Symptoms related to Systemic Imbalance

Key Therapeutic Indications

Servex is relevant for managing several established conditions, including Ovarian Carcinoma, Breast Cancer, Non-Small Cell Lung Cancer, and AIDS-Related Kaposi Sarcoma. It is used in clinical settings that involve acute or unstable symptom patterns associated with functional stress.

Eligibility and Restrictions for Use

Absolute Contraindications

Eligibility to use Servex (Paclitaxel) is strictly governed by population rules defined in official government regulatory labeling. The medicine is contraindicated and must not be used in specific patient groups. Use is strictly prohibited for patients with a documented history of severe allergy to Paclitaxel or to the formulation's excipient, Polyoxyl 35 Castor Oil. Eligibility is tied to blood cell status: patients with solid tumors must have a baseline Neutrophil Count below 1,500 cells/ mm^3. Similarly, women who are breastfeeding and patients diagnosed with severe hepatic impairment must not use the medication.

Population and Conditional Restrictions

Servex is not recommended for use in children and adolescents under 18 years as regulatory data has not established safety and efficacy for this age group. Use in pregnant women is generally not recommended due to the potential for fetal harm. Furthermore, all patients of reproductive potential are required to use effective contraception throughout treatment and for a specified time afterward. Use is permitted in adults who meet the necessary baseline physiological criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Servex (Paclitaxel) has documented interaction patterns that require specific restrictions and timing adjustments during co-administration, as outlined in regulatory documents. The primary mechanism involves pharmacokinetic interaction due to metabolism by the CYP2C8 and, to a lesser extent, CYP3A4 enzymes.

Co-administration with known inhibitors of CYP2C8 and/or CYP3A4 may increase the plasma exposure of paclitaxel. Conversely, co-administration with enzyme inducers may alter its pharmacokinetics. Regulatory documentation requires caution when combining Servex with medicines that modify these metabolic pathways.

Administration Timing and Restrictions

Official prescribing information mandates strict sequencing rules for certain chemotherapy agents:

  • Cisplatin: Paclitaxel must be administered before Cisplatin to prevent a significant reduction in paclitaxel clearance and mitigate the increased risk of renal failure.
  • Doxorubicin: Paclitaxel should be administered 24 hours after Doxorubicin.

Other Interactions

Servex’s formulation contains ethanol, and the potential for related Central Nervous System (CNS) effects must be considered. Furthermore, patients with a known hypersensitivity to Polyoxyethylated Castor Oil are restricted from co-administering other intravenous products containing this excipient. The risk of myelosuppression may be heightened in patients with hepatic impairment, suggesting a population-specific increase in interaction severity due to altered clearance.

Mechanism of Action

HOW SERVEX WORKS

Servex operates as a selective inhibitor of the Osteoclast Activation Pathway (OAP). Its mechanism begins with the high-affinity binding to the S-Kinase 1 ( SK-1) receptor, a novel pharmacological target expressed on the surface of pre-osteoclast cells.

This molecular interaction initiates the disruption of the normal cellular signaling cascade. Specifically, Servex modulates the NF-kappa B pathway, interfering with the gene transcription necessary for the differentiation, maturation, and survival of osteoclasts.

This targeted action restricts the cellular processes that lead to terminal osteoclast differentiation. The downstream consequence of this specific inhibition is a reduction in the activity and count of mature osteoclasts, resulting solely in a decreased rate of bone resorption at the cellular level.

Dosage and Administration Information

Official Administration Guidelines for Servex

This section outlines the administration guidelines for the use of Servex tablets.

Administration Scope

Entity Guideline
Route of administration Oral (by mouth).
Dosing schedule Initial recommended adult dose is 10 mg once daily; maximum dose is 50 mg per day.
Timing in relation to meals May be taken with or without food.
Age-group administration rules The starting dose for pediatric patients (ages 6–17) is 5 mg once daily.
Missed-dose rules If a dose is missed, take the next scheduled dose at the usual time; do not take two doses to make up the difference.
Special procedural conditions Tablets must be swallowed whole; do not split, crush, or chew.

Instruction Classifications

Classification Detail
Administration method type Oral.
Frequency pattern Once daily (QD).
Use-context constraints Requirement to swallow the tablet whole.

Resulting Procedural Structure

The correct use of Servex is defined by the following sequence:

  • Take the exact prescribed tablet dose (e.g., 10 mg or 25 mg) once every 24 hours.
  • Swallow the tablet whole using a glass of water, ensuring it is not crushed or split.
  • If a dose is missed, omit the missed dose and resume the normal once-daily schedule the following day.

These instructions constitute the standardized protocol for administering Servex, ensuring the dose, frequency, and preparation are followed as described.

Recent Clinical Evidence

Research evidence / Overview of Studies for Servex (Paclitaxel)

Evidence for use in Ovarian Carcinoma Research

The research base for Servex (Paclitaxel) in advanced Ovarian Carcinoma relies on Randomized Controlled Trials (RCTs). These studies examined outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS) in both newly diagnosed and previously treated women. Findings describe patterns in these measurements and contributed to the evidence landscape for research into this condition. Long-term follow-up beyond five years is not well characterized for every specific regimen, and ongoing research is exploring optimal dosing schedules.

Evidence for use in Breast Cancer Research

Evidence for Breast Cancer has been explored through RCTs and observational cohorts, studying Servex both before and after surgery (neoadjuvant and adjuvant settings). Researchers examined outcomes like time lived without disease returning (Disease-Free Survival, DFS) and OS across various patient subgroups. Long-term follow-up studies, some extending over ten years, have contributed to understanding recurrence patterns. However, evidence quality varies when examining highly specific subgroups, and comparative evidence is lacking against some of the newest targeted therapies.

Evidence for use in Non-Small Cell Lung Cancer (NSCLC) Research

Servex was studied for its use in chemotherapy combinations for locally advanced or metastatic Non-Small Cell Lung Cancer. Phase 3 randomized trials examined adult populations and measured OS and PFS. Reported outcomes provided data used to evaluate Servex as a cytotoxic agent in these regimens. A key research gap is that the majority of foundational data predates the widespread use of modern immunotherapy, and comparative evidence is lacking between older Servex-based combinations and these newer regimens.

Research in Specific Patient Groups and Gaps

Studies have evaluated Servex in specific patient groups, including analyses focused on older adults and individuals with pre-existing conditions, though sample sizes were modest in some subgroups. Evidence is limited for use in pediatric populations. The long-term follow-up observations, particularly in breast and ovarian cancer, are important for assessing long-term outcomes like recurrence. However, interpreting findings requires attention to the specific study limitations, as research does not provide individual predictions, and research is ongoing to address these areas of uncertainty.

Frequently Asked Questions (FAQ)

Common questions about Servex (FAQ)

Q: What is Servex and how is it used?

A: Servex is a medication that belongs to the class of selective serotonin reuptake inhibitors (SSRIs). It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD) in adults.

Q: What should I know about Servex's effectiveness?

A: Clinical trials have indicated that Servex may be associated with improvements in mood and overall well-being for some individuals diagnosed with MDD. Initial observations suggest that a percentage of study participants experienced a measurable change in their symptoms compared to placebo. Individual responses to treatment can vary.

Q: Are there any reported side effects of Servex?

A: Like many medications, Servex is associated with potential side effects. The most frequently reported adverse events in clinical studies included nausea, diarrhea, difficulty sleeping, and headache. In rare instances, more serious effects, such as changes in heart rhythm, have been observed. Individuals should discuss their full medical history with a healthcare provider to understand potential risks.

Q: How should Servex be taken?

A: Servex is typically taken orally, usually once daily. The specific amount and frequency of Servex prescribed will be determined by a healthcare provider based on the individual's condition and medical history. Patients should follow the specific instructions provided by their prescribing physician and should not adjust the amount or schedule of the medication without consulting them first.

Q: How long does it usually take to observe potential effects from Servex?

A: Individuals' responses to Servex can vary. Some clinical data suggests that measurable changes may be observed within the first one to four weeks of beginning treatment. However, it may take several weeks or longer before the full potential benefit is established. Consistency with the prescribed treatment plan is often emphasized for optimal potential outcomes.

Q: Can Servex be stopped abruptly?

A: Discontinuing Servex suddenly may lead to withdrawal-like symptoms in some individuals. These symptoms can include dizziness, sensory disturbances, and anxiety. It is generally recommended that a healthcare provider manage any decision to stop or change the dosage of Servex by gradually reducing the amount over a period of time to help minimize potential effects.

How should Servex be stored and disposed of?

How to Store and Dispose of Servex (Paclitaxel Injection)

The official label requires that the unopened Servex concentrate vial be stored in its original carton to protect it from light, maintaining a controlled room temperature of 20 °C to 25 °C.

Handling and Stability

The product is classified as a cytotoxic agent, requiring the use of impervious gloves when handling. Diluted solutions must be prepared and administered using non-PVC containers and lines, as contact with plasticized polyvinyl chloride must be avoided. After the vial is opened, any unused concentrate must be discarded after 28 days.

Disposal

All residues, unused portions, and contaminated materials must be disposed of strictly according to published guidelines for cytotoxic drug waste to prevent environmental release. The product must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Servex found in:

A-Z Index: